<DOC>
	<DOCNO>NCT01983878</DOCNO>
	<brief_summary>The purpose study evaluate progression-free survival participant gastric gastroesophageal junction cancer disease progression follow first-line therapy undergo treatment ramucirumab .</brief_summary>
	<brief_title>A Study Ramucirumab Treating Japanese Participants With Metastatic Gastric Gastroesophageal Junction Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Histologically cytologically confirm gastric carcinoma , include gastric adenocarcinoma Gastroesophageal Junction ( GEJ ) adenocarcinoma Metastatic disease locally recurrent , unresectable disease Measurable disease and/or evaluable disease Experienced disease progression within 4 month last dose firstline therapy metastatic disease , within 6 month last dose adjuvant therapy Life expectancy least 3 month Resolution Grade less equal 1 National Cancer Institute Common Terminology Criteria Adverse , Version 4.03 , clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy Eastern Cooperative Oncology Group performance status score 01 Has adequate organ function Must postmenopausal , surgically sterile , use effective contraception ( hormonal barrier method ) , sexually active Female participant childbearing potential must negative serum urine pregnancy test within 7 day prior enrollment Documented and/or symptomatic brain leptomeningeal metastases Bone metastasis Experienced Grade 3/4 gastrointestinal ( GI ) bleed within 3 month prior enrollment Experienced arterial thromboembolic event within 6 month prior enrollment Ongoing active significant infection , symptomatic congestive heart failure ( CHF ) , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , uncontrolled thromboembolic hemorrhagic disorder , serious uncontrolled medical disorder opinion investigator Ongoing active psychiatric illness social situation would limit compliance study requirement Blood pressure abnormal range despite standard medical management Has serious nonhealing wound , ulcer , bone fracture Received chemotherapy , radiotherapy , immunotherapy , target therapy gastric cancer Received investigational therapy within 30 day prior enrollment Undergone major surgery within 28 day prior enrollment , subcutaneous venous access device placement within 7 day prior enrollment Received prior therapy agent directly inhibit vascular endothelial growth factor ( VEGF ) vascular endothelial growth factor receptor 2 ( VEGFR2 ) activity ( include bevacizumab ) , antiangiogenic agent Receiving chronic therapy nonsteroidal antiinflammatory drug receive antiplatelet agent . Aspirin use dose 325 milligram per day permit Has elective plan major surgery perform course clinical study Has know allergy treatment component Pregnant breastfeed Have positive test result human immunodeficiency virus , hepatitis B , hepatitis C antibodies Known alcohol drug dependency Previous concurrent malignancy except basal squamous cell skin cancer ( nonmelanoma ) and/or preinvasive carcinoma cervix , mucosal gastrointestinal uterine carcinoma , solid tumor treat curatively without evidence recurrence least 3 year prior enrollment Currently enrol clinical trial involve investigational product nonapproved use drug device ( study drug/device use study ) , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>